Glactone Pharma
Stage
Seed | AliveTotal Raised
$850KLast Raised
$850K | 9 yrs agoAbout Glactone Pharma
Glactone Pharma is developing a drug for the treatment of castration resistant prostate cancer. Research has shown that the natural product galiellalactone can modulate a signaling protein (STAT3) that is over activated in cancer cells. The goal is to develop drugs against metastasizing cancer where galiellalactone is used as a chemical starting point to make new novel, patentable compounds.
Missing: Glactone Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Glactone Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Glactone Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Glactone Pharma is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Glactone Pharma Patents
Glactone Pharma has filed 5 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immune system
- Proteins
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/5/2017 | 9/22/2020 | Transcription factors, Clusters of differentiation, Proteins, Signal transduction, Immune system | Grant |
Application Date | 12/5/2017 |
|---|---|
Grant Date | 9/22/2020 |
Title | |
Related Topics | Transcription factors, Clusters of differentiation, Proteins, Signal transduction, Immune system |
Status | Grant |
Latest Glactone Pharma News
Dec 9, 2019
Swedish life science company Aqilion says it is selling its entire stake in portfolio company Glactone… To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. PLUS... you can receive the Pharma Letter headlines and news roundup email free forever Only £77 per month or £820 per year No-limits access to our site with up-to-the minute news Personalised news and email alerts Online discussion forums and Q&A section RSS news feeds that you can add to your favourite reader, or website Daily news email alert, with the breaking news stories and news roundup
Glactone Pharma Frequently Asked Questions (FAQ)
Where is Glactone Pharma's headquarters?
Glactone Pharma's headquarters is located at Kullagatan 8, Helsingborg.
What is Glactone Pharma's latest funding round?
Glactone Pharma's latest funding round is Seed.
How much did Glactone Pharma raise?
Glactone Pharma raised a total of $850K.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.